PMID- 23238663
OWN - NLM
STAT- MEDLINE
DCOM- 20130918
LR  - 20211021
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 36
IP  - 4
DP  - 2013 Apr
TI  - Platelet redox balance in diabetic patients with hypertension improved by n-3 
      fatty acids.
PG  - 998-1005
LID - 10.2337/dc12-0304 [doi]
AB  - OBJECTIVE: Patients with type 2 diabetes mellitus (T2DM) are at increased risk of 
      developing cardiovascular disease, largely as a result of defective production of 
      cardioprotective nitric oxide and a concomitant rise in oxidative stress. Dietary 
      interventions that could reverse this trend would be extremely beneficial. Here 
      we investigated whether dietary n-3 polyunsaturated fatty acid (n-3 PUFA) 
      supplementation positively affected platelet nitroso-redox imbalance. RESEARCH 
      DESIGN AND METHODS: We randomized hypertensive T2DM patients (T2DM HT; n = 22) 
      and age-and-sex matched hypertensive study participants without diabetes (HT 
      alone; n = 23) in a double-blind, crossover fashion to receive 8 weeks of n-3 
      PUFAs (1.8 g eicosapentaenoic acid and 1.5 g docosahexaenoic acid) or identical 
      olive oil capsules (placebo), with an intervening 8-week washout period. Platelet 
      nitrite and superoxide were measured and compared before and after treatment; 
      8-isoprostane was determined by ELISA and subcellular compartmentalization of the 
      NAD(P)H oxidase subunit p47-phox examined by Western blotting. RESULTS: The n-3 
      PUFA supplementation reduced 8-isoprostane and superoxide levels in platelets 
      from T2DM HT, but not HT alone, participants, without effect on nitrite 
      production. This coincided with a significant decrease in p47-phox membrane 
      localization and a similar reduction in superoxide to that achieved with 
      apocynin. At baseline, a subcohort of T2DM HT and HT alone participants showed 
      evidence of nitric oxide synthase (NOS)-derived superoxide production, indicating 
      defective enzymatic activity. This was reversed significantly in T2DM HT 
      participants after treatment, demonstrating improved NOS function. CONCLUSIONS: 
      Our finding that n-3 PUFAs diminish platelet superoxide production in T2DM HT 
      patients in vivo suggests a therapeutic role for these agents in reducing the 
      vascular-derived oxidative stress associated with diabetes.
FAU - McDonald, Denise M
AU  - McDonald DM
AD  - Centre for Vision and Vascular Science, Queen's University Belfast, Belfast, UK. 
      d.mcdonald@qub.ac.uk
FAU - O'Kane, Fiona
AU  - O'Kane F
FAU - McConville, Maeve
AU  - McConville M
FAU - Devine, Adrian B
AU  - Devine AB
FAU - McVeigh, Gary E
AU  - McVeigh GE
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20121213
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Fatty Acids, Omega-3)
RN  - 11062-77-4 (Superoxides)
RN  - 27415-26-5 (8-epi-prostaglandin F2alpha)
RN  - B7IN85G1HY (Dinoprost)
SB  - IM
MH  - Aged
MH  - Blood Platelets/*metabolism
MH  - Cross-Over Studies
MH  - Diabetes Mellitus, Type 2/*blood/*diet therapy
MH  - Dinoprost/analogs & derivatives/metabolism
MH  - Double-Blind Method
MH  - Fatty Acids, Omega-3/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hypertension/*blood/*diet therapy
MH  - Male
MH  - Middle Aged
MH  - Oxidation-Reduction
MH  - Superoxides/metabolism
PMC - PMC3609528
EDAT- 2012/12/15 06:00
MHDA- 2013/09/21 06:00
PMCR- 2014/04/01
CRDT- 2012/12/15 06:00
PHST- 2012/12/15 06:00 [entrez]
PHST- 2012/12/15 06:00 [pubmed]
PHST- 2013/09/21 06:00 [medline]
PHST- 2014/04/01 00:00 [pmc-release]
AID - dc12-0304 [pii]
AID - 0304 [pii]
AID - 10.2337/dc12-0304 [doi]
PST - ppublish
SO  - Diabetes Care. 2013 Apr;36(4):998-1005. doi: 10.2337/dc12-0304. Epub 2012 Dec 13.